We use cookies to analyze site usage and improve your experience. You can accept all, reject non-essential, or customize. See our Privacy Policy.
HRT Patches
Medically reviewed by Dr. Ana Lisa Carr, MD, MBA · Last reviewed May 10, 2026
An estradiol patch — also called an HRT patch, estrogen patch, or transdermal estrogen patch — delivers bioidentical estradiol through the skin into the bloodstream. It is the most-prescribed and best-studied form of menopausal hormone therapy in the United States. Because the hormone bypasses first-pass liver metabolism, transdermal estradiol does not raise hepatic clotting factors the way oral estrogen does, so the venous thromboembolism (VTE) risk is meaningfully lower (BMJ 2019, NAMS 2022). Kindr connects you with a board-certified menopause doctor licensed in your state who can prescribe Vivelle-Dot, Climara, Minivelle, Alora, or a compounded transdermal preparation — typically within 24–72 hours of intake, with free shipping to all 50 states.
A transdermal estradiol patch is a thin adhesive square containing a reservoir or matrix of 17β-estradiol — the same molecule your ovaries produced in your reproductive years. Worn on the lower abdomen or upper buttock, it releases a steady micro-dose of estradiol through the skin into the bloodstream over the course of several days. Because the hormone enters circulation directly rather than passing through the liver first, it avoids the surge in hepatic clotting factors and inflammatory markers that oral estrogen produces.
Patches are FDA-approved for moderate-to-severe vasomotor symptoms (hot flashes, night sweats), genitourinary syndrome of menopause, and prevention of postmenopausal osteoporosis. They are the preferred delivery method for most women in current NAMS and ACOG guidance.
Online prescribing of estradiol patches is legal in all 50 states when done by a licensed physician through a compliant telehealth visit. Kindr's intake captures the same clinical information an in-person visit would — symptom inventory, medical history, cardiovascular and clot risk factors, family history, and your goals. A board-certified clinician reviews the intake (no scheduled appointment required), discusses any clarifying questions by message, and sends the prescription to a partner pharmacy or your local pharmacy.
Most Kindr patients receive their first patch shipment within 3–5 days of prescription approval. Refills are automatic and dose adjustments are message-based.
| Brand | Type | Wear schedule | Dose range (mg/day) | Notes |
|---|---|---|---|---|
| Vivelle-Dot | Matrix | Twice weekly | 0.025 – 0.1 | Small, discreet; strong adhesion in studies |
| Minivelle | Matrix | Twice weekly | 0.0375 – 0.1 | Smallest patch on market; low skin reaction rate |
| Climara | Matrix | Once weekly | 0.025 – 0.1 | Lowest weekly handling; larger patch |
| Alora | Matrix | Twice weekly | 0.025 – 0.1 | Strong adhesion in active patients |
| Estraderm | Reservoir | Twice weekly | 0.05 / 0.1 | Older reservoir design; higher skin reaction rate |
| Menostar | Matrix | Once weekly | 0.014 | Ultra-low dose; bone-prevention indication |
| Compounded | Cream/gel | Daily | Custom | Fine titration when commercial doses don't fit |
A 2019 BMJ study of ~80,000 women found that oral conjugated equine estrogen approximately doubled VTE risk compared to baseline, while transdermal estradiol showed no statistically significant increase. The Endocrine Society, NAMS, and ACOG all state that for women with cardiovascular risk factors, migraine with aura, elevated baseline VTE risk, hypertriglyceridemia, gallbladder disease, or active liver disease, transdermal estrogen is preferred over oral.
On vasomotor symptom efficacy, patches and pills are equivalent at comparable systemic estradiol levels. The differences are in safety and convenience — not in how well they treat hot flashes, sleep, or mood.
| Method | Frequency | Bypasses liver | VTE / stroke risk | Best for |
|---|---|---|---|---|
| Patch | 1–2x/week | ✓ Yes | Lower | Most women — first-line |
| Gel | Daily | ✓ Yes | Lower | Fine dose flexibility |
| Spray | Daily | ✓ Yes | Lower | Skin-sensitive patients |
| Cream (compounded) | Daily | ✓ Yes | Lower | Custom dosing |
| Oral tablet | Daily | ✗ No | Higher | Patient preference, low VTE risk |
| Vaginal ring | 90 days | Partial | Lowest systemic | Local genitourinary symptoms |
Many women start on an oral tablet and switch to a patch later — often after a clot scare, a migraine pattern change, or a new cardiovascular risk factor. The transition is straightforward: most clinicians stop the oral dose on day one of the patch with no taper. Equivalent dose mapping is roughly: 1 mg oral estradiol ≈ 0.05 mg/day patch. Your Kindr provider will pick the starting patch dose based on what symptom control you already had on the pill.
For women within 10 years of menopause onset or under age 60 with no contraindications, the NAMS 2022 Position Statement and ACOG both conclude that benefits of systemic estrogen therapy generally outweigh the risks. Your Kindr clinician completes a full risk screen before prescribing.
If you have a uterus, you almost certainly need progesterone alongside the estradiol patch. Unopposed estrogen stimulates the endometrium and significantly raises the risk of endometrial hyperplasia and cancer. The most-studied protocol is oral micronized progesterone (Prometrium) 100 mg nightly continuous, or 200 mg nightly for 12 days/month in cyclic regimens. See our progesterone-menopause guide for the full clinical picture, including the sleep benefit, breast-cancer signal, and Prometrium-vs-medroxyprogesterone comparison.
After your intake, your provider evaluates symptom severity, medical history, and cardiovascular and clot risk factors. If a patch is appropriate, you typically start at 0.025–0.05 mg/day with planned reassessment at week 4 and week 8. Dose adjustments are routine and message-based — no need to schedule a new visit. Most Kindr patients reach symptom control by week 8–12. If you want a clinician with deep menopause training, see our menopause specialist guide.
Yes. Estradiol patches are prescribed online by Kindr's board-certified menopause doctors in all 50 states. Intake takes about 10 minutes; a clinician reviews within 24–72 hours and sends the prescription to your pharmacy. Free shipping included.
Kindr plans start at $79 for the first month, $89/month thereafter — including the doctor consultation, the patch prescription, unlimited messaging, and shipping. HSA/FSA eligible. Generic estradiol patches at retail pharmacies typically run $20–$60/month without coverage; brand-name Vivelle-Dot or Climara can run $150–$350/month without insurance.
Generic estradiol matrix patches and Vivelle-Dot are the most commonly prescribed in the U.S., followed by Climara (once-weekly) and Minivelle (smallest patch).
Most women start at 0.025–0.05 mg/day. Severe vasomotor symptoms or surgical menopause may warrant starting at 0.0375–0.05 mg/day. Your clinician titrates based on symptom response at weeks 4 and 8.
They are clinically equivalent at matched doses. Vivelle-Dot is smaller and changed twice weekly; Climara is larger and changed once weekly. Choice is driven by convenience preference and skin tolerance.
Lower abdomen or upper buttock, on clean dry skin. Avoid the breasts, waistband area, and irritated skin. Rotate sites with each change.
Either once weekly (Climara, Menostar) or twice weekly (Vivelle-Dot, Minivelle, Alora, Estraderm) depending on the product. The prescription label specifies the schedule.
They can, especially in hot weather or after long swims. If a patch falls off in the first half of its wear period, replace it; if late, wait until the next scheduled change.
For VTE, stroke, and gallbladder risk: yes. Transdermal estradiol does not raise hepatic clotting factors the way oral estrogen does (BMJ 2019, NAMS 2022). For symptom efficacy they are equivalent.
No. Randomized trials have not shown a consistent weight effect from transdermal estradiol; midlife weight gain is largely driven by insulin resistance, sleep loss, and muscle decline.
Yes. Brief water exposure and sweating do not affect adhesion or absorption. Avoid extended hot-tub or sauna sessions, which can soften the adhesive.
Many women notice improvement in hot flashes and sleep within 2–4 weeks. Full effect is typically reached by 8–12 weeks.
If you have a uterus, yes. Progesterone protects the uterine lining from estrogen stimulation. The most-studied option is oral micronized progesterone (Prometrium) 100 mg nightly.
Yes. The active ingredient is 17β-estradiol — molecularly identical to the estradiol the ovaries produce. This is true of all FDA-approved estradiol patches.
Yes, and it is a common reason women come to Kindr. Most clinicians stop the pill on day one of the patch with no taper. 1 mg oral estradiol ≈ 0.05 mg/day patch.
NAMS 2022 states there is no arbitrary limit. Duration is individualized to symptom control, risk profile, and shared decision-making with your clinician. Many women stay on transdermal HRT for 5–10+ years.
Medically reviewed by Dr. Ana Lisa Carr, MD, MBA
Board-Certified Family Medicine Physician · Lead Provider / Medical Reviewer
NPI 1689841744 · Last reviewed: May 10, 2026
Currently onboarding clinicians in all 50 states.
Estradiol is the primary estrogen prescribed for menopause symptoms. Kindr’s board-certifi…
Progesterone →Progesterone is essential for most women on HRT. Board-certified doctors prescribe bioiden…
HRT Side Effects →Understanding HRT side effects — breast tenderness, bloating, spotting, mood changes. What…
Bioidentical Hormones →Bioidentical hormones are chemically identical to your body’s own hormones. Kindr prescrib…
Information on this page is for educational purposes only. Prescription medications require clinical evaluation and provider approval. Individual results vary. Not an emergency service.